Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

作者：Salih Tünbekici, Gökhan Şahin, Sercan Ön, Ahmet Fatih Oruç, Melek Karakurt Eryılmaz, Abdullah Sakin, Alper Coşkun, Mustafa Seyyar, Fatma Keskin Uzundere, Erdem Kolemen, Devrim Çabuk, Safa Can Efil, Teyfik Demi̇r, Emine Türkmen, Ferhat Ekinci, Aytac Terzi, Taha Koray Şahin, Deniz Can Güven, Sercan Aksoy, Ali Aytac, Özge Demirkıran, Bilgin Demir, Ismet Culcuoglu, Mustafa Ersoy, Esra Asarkaya, Ufuk Camanlı, Barış Gezici, Ahmet Özveren, Alper Sevınc, Sait Kitaplı, Ahmet Ünlü, Banu Öztürk, Alper Türkel, Mutlu Doğan, Ferit Aslan, Enes Yeşilbaş, Esmanur Kaplan, Teoman Şakalar, Elif Şahin, Gamze Emin, Esra Aşık, Atilla Yıldırım, Taliha Guclu, İrem Uğurlu, Fatma Akdag Kahvecioglu, İlhan Hacıbekiroğlu, Ibrahim Tunbekici, Selami Bayram, Ali Kaya, Nargız Majidova, Özge Yalıcı, Murat Karateke, Nilüfer Avcı, Burcu Belen, Hamit Bal, Oğuzcan Kınıkoğlu, Fatma Paksoy Türköz, Eda Tanrıkulu Şimşek, Oguz Altınok, Tuğçe Kübra Güneş, Yunus Emre Altıntaş, Murad Guliyev, Gökhan Öztürk, Di̇lek Erdem, Yakup Düzköprü, Ali̇ İnal, Ali Kaan Güren, Nilgün Yıldırım, Tuğba Akın Telli, Yurdagul Danacı, Umut Aydın, Elvina Almuradova, Hasan Çağrı Yıldırım, Pınar Gürsoy, Mehmet Alı Nahıt Şendur, Erdem Göker · 发表于：International Journal of Cancer · 年份：2025 · DOI：10.1002/ijc.70213 · 被引用次数：1 · 研究领域：HER2/EGFR in Cancer Research、Advanced Breast Cancer Therapies、Cancer Treatment and Pharmacology

Sacituzumab govitecan (SG) is an antibody-drug conjugate approved for metastatic or unresectable locally advanced triple-negative breast cancer (mTNBC) after at least two prior systemic therapies, yet real-world evidence remains limited. We conducted a retrospective, multicenter study including 285 patients with unresectable locally advanced or metastatic TNBC treated with SG across 52 oncology centers in Turkey. Median progression-free and overall survival were 5.4 months (95% confidence interval [CI], 4.6-6.2) and 12.2 months (95% CI, 10.5-13.9), respectively, with a 12-month overall survival rate of 49.2%. The objective response rate and disease control rate in evaluable patients were 36.8% and 63.9%. Grades 3-4 adverse events, mainly neutropenia, occurred in 44.2% of patients. Dose reductions were needed in 20% of cases; no treatment-related deaths were reported. Our large real-world cohort reinforces the effectiveness and manageable safety profile of SG, mirroring pivotal trials, and highlights its value as a therapeutic option in diverse and heavily pretreated mTNBC populations.